NCT03012880: Phase 2 - Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab NDMM
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER
NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY